CLAIMS

~~1. A method of~~

1. Use of a Plasma Fraction in the manufacture of a medicament for treating a subject diagnosed with a cognitive impairment, ~~the method comprising, administering an effective amount of a Plasma Fraction~~ wherein the medicament is to be administered using a Pulse Dosed dosing regimen~~.~~

~~2. The method of claim 1~~, and wherein the Plasma Fraction is a ~~Plasma Protein Fraction.~~

~~3. The method of claim 2 wherein the Plasma Protein Fraction comprises between 83% to~~ Human Albumin Solution (HAS) comprising at least 95% albumin~~.~~ in relation to total protein.

~~4.~~

2. The ~~method~~use of claim ~~3~~1 wherein the ~~Plasma Protein Fraction~~HAS is a commercially available ~~Plasma Protein Fraction~~HAS.

~~5. The method of claim 1 wherein the Plasma Fraction is a protein enriched plasma protein product.~~

3. ~~6. The method~~The use of any of the preceding claims wherein the ~~Plasma Fraction~~HAS is derived from plasma from a pool of~~young individuals~~humans 40 years of age or younger.

4. ~~7. The method~~The use of any of the preceding claims wherein the HAS is produced from a human blood product.

5. The use of any of the preceding claims wherein the ~~Plasma Fraction is produced from a mammalian blood product.~~

~~8. The method of claim 7 wherein the mammalian blood product is a human blood product.~~

~~9. A method of treating a~~ subject ~~diagnosed with a cognitive impairment, the method comprising, administering an effective amount of young plasma using a Pulse Dosed dosing regimen.~~

~~10. The method of any of the preceding claims further comprising monitoring the subject~~is monitored for improved cognitive function.

6. ~~11.~~ The ~~method~~use of any of the preceding claims wherein the subject is a mammal.

7. ~~12.~~ The ~~method~~use of claim ~~11~~6 wherein the mammal is a human.

8. ~~13. The method~~The use of any of the preceding claims wherein according to the Pulse Dosed dosing regimen the HAS is to be administered for five to seven consecutive days.

9. The use of any of the preceding claims wherein the ~~Plasma Fraction or young plasma is derived from a pool of young individuals.~~effective amount of HAS is 100 ml.

10. ~~14. The method of any of the preceding claims wherein the Pulse Dosed dosing regimen comprises administering the Plasma Fraction or young plasma for five to seven consecutive days.~~

~~15. The method of any of the preceding claims~~use of any of claims 1 to 8 wherein the effective amount ~~is 100 ml.~~

~~16. The method of any of claims 1 to 14 wherein the effective amount~~of HAS is 250 ml.

11. ~~17. The method of any~~use of any of the preceding claims wherein the subject follows an exercise regimen after the Pulsed Dosed dosing regimen has been fully administered.

12. ~~18. The method~~use of any of claims 1 to ~~17~~11 wherein the administering increases the number of synapses in the subject.

~~19.~~

13. The ~~method~~use of any of claims 1 to ~~17~~11 wherein the administering increases synaptic integrity of the subject.

14. ~~20. The method~~use of any of claims 1 to ~~17~~11 wherein the administering increases neuronal network integrity of the subject.

15. ~~21. The method~~use of any of claims 1 to ~~17~~11 wherein the administering increases neuronal connectivity of the subject.

16. ~~22. A~~ kit suitable for use in treating a subject for a cognitive disorder, the kit comprising a container comprising ~~a Plasma Fraction~~HAS as described in any of claims 1 to ~~8~~4 and ~~13~~7.